Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
11 hedge funds and large institutions have $161K invested in Evoke Pharma in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
38% more capital invested
Capital invested by funds: $117K → $161K (+$44.2K)
22% more funds holding
Funds holding: 9 → 11 (+2)
0% less ownership
Funds ownership: 0.16% → 0.15% (-0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$375 |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$66 |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$44 |
| 4 |
Morgan Stanley
New York
|
+$22 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.56K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$1K |
| 3 |
BlackRock
New York
|
-$353 |
| 4 |
HIA
Harbor Investment Advisory
Lutherville,
Maryland
|
-$154 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $80K | – | – | – |
|
2
Geode Capital Management
Boston,
Massachusetts
| $55K | – | – | – |
|
|
3
BlackRock
New York
| $20.9K | -$353 | -16 | -2% |
|
4
UBS Group
Zurich,
Switzerland
| $2.97K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2K | -$2.56K | -116 | -62% |
|
|
LC
6
Lindbrook Capital
Calabasas,
California
| $222 | – | – | – |
|
|
7
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $86 | +$66 | +3 | New |
|
8
Wells Fargo
San Francisco,
California
| $43 | – | – | – |
|
|
9
Morgan Stanley
New York
| $19 | +$22 | +1 | New |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $13 | – | – | – |
|
|
NA
11
NewEdge Advisors
New Orleans,
Louisiana
| $1 | +$375 | +17 | New |
|
|
12
Group One Trading
Chicago,
Illinois
| – | -$1K | -28 | Closed |
|
|
HIA
13
Harbor Investment Advisory
Lutherville,
Maryland
| – | -$154 | -7 | Closed |
|
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$44 | +2 | New |
|
EVOK Hedge Fund Activity: Q4 2022 in Review
11 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2022, worth a combined $161K — up 38% from $117K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EVOK positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was NewEdge Advisors, opening a new position worth an estimated $375. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.56K.
- 11 institutional investors held Evoke Pharma (EVOK) as of Q4 2022, up from 9 in Q3 2022.
- Funds reported $161K of Evoke Pharma stock for Q4 2022, up 38% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q4 2022 and 2 closed out, a net change of +2 holders.
- The largest Evoke Pharma buyer in Q4 2022 was NewEdge Advisors, an estimated $375 added.
- The largest Evoke Pharma seller in Q4 2022 was Tower Research Capital (TRC), an estimated $2.56K sold.
Based on aggregated 13F filings for Q4 2022.